CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 38(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2017-2022

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11214571 - Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof (2022-01-04),

2. 10813936 - Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate (2020-10-27),

3. 10799505 - Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate (2020-10-13),

4. 10285993 - Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate (2019-05-14),

5. 10172861 - Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate (2019-01-08),

6. 9790206 - Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof (2017-10-17),

7. 9782414 - Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate (2017-10-10),

Title: Derrick Juengst: Innovator in Pharmaceutical Development

Introduction

Derrick Juengst, based in Boulder, CO, is a notable inventor with a focus on pharmaceutical innovations. With a total of seven patents to his name, Juengst has made significant contributions, particularly in the development of compounds that target complex health issues such as cancer.

Latest Patents

His latest patents include processes for the preparation of critical compounds like (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and its salts. This compound acts as a tyrosine kinase (TRK) inhibitor, which is vital for treating various forms of cancer. Other relevant processes involve the preparation of several derivatives, showcasing Juengst's expertise in medicinal chemistry and drug formulation.

Career Highlights

Throughout his career, Derrick Juengst has worked with prestigious companies such as Array Biopharma and Loxo Oncology. His role in these organizations has allowed him to contribute to groundbreaking research aimed at creating effective treatment options for patients suffering from serious conditions.

Collaborations

Collaboration has been key to Juengst's success. He has worked alongside esteemed colleagues, including Alisha B Arrigo and Khalid Ali Shah, who share his commitment to advancing pharmaceutical science and improving patient outcomes.

Conclusion

Derrick Juengst's innovative spirit and dedication to research have led to meaningful advancements in the pharmaceutical industry. His patents reflect a deep understanding of complex biochemical processes and a commitment to overcoming the challenges posed by diseases like cancer. Through his work, Juengst continues to impact the lives of many, making him a significant figure in the field of pharmaceutical innovation.

This text is generated by artificial intelligence and may not be accurate.